Axillary management in breast cancer: What's new for 2012?

Breast

Volumn 21, Issue 3, 2012, Pages 411-415

  Cody, Hiram S ^a   Houssami, Nehmat ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Axilla; Micrometastases; Needle biopsy; Recurrence; Sentinel node; Staging; Ultrasound

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE INHIBITOR;

ARTICLE; AXILLARY LYMPH NODE EXTIRPATION; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PATIENT CARE PLANNING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; ULTRASOUND; ULTRASOUND GUIDED NEEDLE BIOPSY;

EID: 84862542345     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.01.011     Document Type: Article

References (58)

1. Halsted W.S. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins hospital from June 1889 to January 1894. Johns Hopkins Hosp Rep 1894, (4):297-350.
2. Morton D.L., Wen D.R., Wong J.H., Economou J.S., Cagle L.A., Storm F.K., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
3. Krag D.N., Weaver D.L., Alex J.C., Fairbank J.T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993, 2:335-340.
4. Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391-401.
5. Houssami N., Ciatto S., Turner R.M., Cody H.S., Macaskill P. Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg 2011 August, 254(2):243-251.
6. Ciatto S., Brancato B., Risso G., Ambrogetti D., Bulgaresi P., Maddau C., et al. Accuracy of fine needle aspiration cytology (FNAC) of axillary lymph nodes as a triage test in breast cancer staging. Breast Cancer Res Treat 2007 May, 103(1):85-91.
7. Cooper K.L., Harnan S., Meng Y., Ward S.E., Fitzgerald P., Papaioannou D., et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2011 March, 37(3):187-198.
8. Houssami N., Hayes D.F. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer?. CA Cancer J Clinicians 2009 September, 59(5):290-302.
9. Morrow M., Waters J., Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011 November 19, 378(9805):1804-1811.
10. Mortellaro V.E., Marshall J., Singer L., Hochwald S.N., Chang M., Copeland E.M., et al. Magnetic resonance imaging for axillary staging in patients with breast cancer. J Magn Reson Imaging 2009 August, 30(2):309-312.
11. Brennan M.E., Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 2011, 21:112-123.
12. Wahl R.L., Siegel B.A., Coleman R.E., Gatsonis C.G. PET study group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004 January 15, 22(2):277-285.
13. Stadnik T.W., Everaert H., Makkat S., Sacre R., Lamote J., Bourgain C. Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging-initial findings. Eur Radiol 2006 October, 16(10):2153-2160.
14. Ueda S., Tsuda H., Asakawa H., Omata J., Fukatsu K., Kondo N., et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 2008, 8:165.
15. Weaver D.L., Krag D.N., Ashikaga T., Harlow S.P., O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000 March 1, 88(5):1099-1107.
16. Turner R.R., Ollila D.W., Krasne D.L., Giuliano A.E. Histologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997, 226:271-278.
17. Kim T., Giuliano A.E., Lyman G.H. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer 2006 January 1, 106(1):4-16.
18. Veronesi U., Paganelli G., Viale G., Luini A., Zurrida S., Galimberti V., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. New Engl J Med 2003 August 7, 349(6):546-553.
19. Krag D.N., Anderson S.J., Julian T.B., Brown A.M., Harlow S.P., Ashikaga T., et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007 October, 8(10):881-888.
20. Mansel R.E., Fallowfield L., Kissin M., Goyal A., Newcombe R.G., Dixon J.M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006 May 3, 98(9):599-609.
21. Zavagno G., De Salvo G.L., Scalco G., Bozza F., Barutta L., Del B.P., et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the sentinella/GIVOM trial. Ann Surg 2008 February, 247(2):207-213.
22. Gill G. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009 February, 16(2):266-275.
23. Weaver D.L., Ashikaga T., Krag D.N., Skelly J.M., Anderson S.J., Harlow S.P., et al. Effect of occult metastases on survival in node-negative breast cancer. New Engl J Med 2011 February 3, 364(5):412-421.
24. Rutgers E.J. Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol 2008 February 10, 26(5):698-702.
25. Cody H.S., Borgen P.I. State-of-the-art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at memorial Sloan-Kettering cancer center. Surg Oncol 1999, 8:85-91.
26. McMasters K.M., Tuttle T.M., Carlson D.J., Brown C.M., Noyes R.D., Glaser R.L., et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 2000, 18:2560-2566.
27. Clarke D., Newcombe R.G., Mansel R.E. The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol 2004 March, 11(Suppl. 3):211S-215S.
28. van der Ent F.W., Kengen R.A., van der Pol H.A., Povel J.A., Stroeken H.J., Hoofwijk A.G. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001 July, 234(1):79-84.
29. Estourgie S.H., Tanis P.J., Nieweg O.E., Valdes Olmos R.A., Rutgers E.J., Kroon B.B. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003 October, 10(8):935-941.
30. Farrus B., Vidal-Sicart S., Velasco M., Zanon G., Fernandez P.L., Munoz M., et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. Int J Radiat Oncol Biol Phys 2004 November 1, 60(3):715-721.
31. Leidenius M.H., Krogerus L.A., Toivonen T.S., Leppanen E.A., von Smitten K.A. The clinical value of parasternal sentinel node biopsy in breast cancer. Ann Surg Oncol 2006 March, 13(3):321-326.
32. Madsen E., Gobardhan P., Bongers V., Albregts M., Burgmans J., De H.P., et al. The impact on post-surgical treatment of sentinel lymph node biopsy of internal mammary lymph nodes in patients with breast cancer. Ann Surg Oncol 2007 April, 14(4):1486-1492.
33. Heuts E.M., Van der Ent F.W.C., von Meyenfeldt M.F., Voogd A.C. Internal mammary lymph drainage and sentinel node biopsy in breast cancer - a study on 1008 patients. Eur J Surg Oncol (EJSO) 2009 March, 35(3):252-257.
34. van Deurzen C.H., Vriens B.E., Tjan-Heijnen V.C., van der Wall E., Albregts M., van H.R., et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer 2009 December, 45(18):3124-3130.
35. Dowlatshahi K., Fan M., Snider H.C., Habib F.A. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997 October 1, 80(7):1188-1197.
36. Tan L.K., Giri D., Hummer A.J., Panageas K.S., Brogi E., Norton L., et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008 April 10, 26(11):1803-1809.
37. Chen S.L., Hoehne F.M., Giuliano A.E. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007 December, 14(12):3378-3384.
38. de B.M., van Dijck J.A., Bult P., Borm G.F., Tjan-Heijnen V.C. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010 March 17, 102(6):410-425.
39. Bilimoria K.Y., Bentrem D.J., Hansen N.M., Bethke K.P., Rademaker A.W., Ko C.Y., et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009 June 20, 27(18):2946-2953.
40. Cote R., Giuliano A.E., Hawes D., Ballman K.V., Whitworth P.W., Blumencranz P.W., et al. ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol 2010 June 20, 28(Suppl. 18):CRA504. [Meeting Abstracts].
41. Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., Whitworth P.W., Blumencranz P.W., et al. Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011 February 9, 305(6):569-575.
42. Giuliano A.E., McCall L., Beitsch P., Whitworth P.W., Blumencranz P., Leitch M., et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American college of surgeons oncology group Z0011 randomized trial. Ann Surg 2010, 252:426-433.
43. Giuliano A.E., McCall L.M., Beitsch P.D., Whitworth P.W., Morrow M., Blumencranz P.W., et al. ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 2010 June 20, 28(Suppl. 18):CRA506. [Meeting Abstracts].
44. Straver M.E., Meijnen P., van T.G., van de Velde C.J., Mansel R.E., Bogaerts J., et al. Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol 2010 February 10, 28(5):731-737.
45. Brogi E., Torres-Matundan E., Tan L.K., Cody H.S. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol 2005 February, 12(2):173-180.
46. McLaughlin S.A., Ochoa-Frongia L.M., Patil S.M., Cody H.S., Sclafani L.M. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J Am Coll Surgeons 2008 January, 206(1):76-82.
47. Giuliano A.E., Dale P.S., Turner R.R., Morton D.L., Evans S.W., Krasne D.L. Improved staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995, 3:394-401.
48. Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 2000, 88:971-977.
49. Cserni G., Gregori D., Merletti F., Sapino A., Mano M.P., Ponti A., et al. Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004 October, 91(10):1245-1252.
50. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., Boolbol S.K., Fey J.V., Tan L.K., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003 December, 10(10):1140-1151.
51. Coutant C., Olivier C., Lambaudie E., Fondrinier E., Marchal F., Guillemin F., et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol 2009 June 10, 27(17):2800-2808.
52. Cserni G., Boross G., Maraz R., Leidenius M.H.K., Meretoja T.J., Heikkila P.S., et al. Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. Surg Oncol 2011, [published online: December 2011]. 10.1016/j.suronc.2011.12.001.
53. Bosscher J., Barnhill D., O'Connor D., Doering D., Nash J., Park R. Osseous metaplasia in ovarian papillary serous cystadenocarcinoma. Gynecol Oncol 1990 November, 39(2):228-231.
54. Weber W.P., Barry M., Stempel M.M., Junqueira M.J., Eaton A.A., Patil S.M., et al. A 10-year trend analysis of sentinel lymph node frozen section and completion axillary dissection for breast cancer: are these procedures becoming obsolete?. Ann Surg Oncol 2011 June 7.
55. Haffty B.G., Hunt K.K., Harris J.R., Buchholz T.A. Positive sentinel nodes without axillary dissection: implications for the radiation oncologist. J Clin Oncol 2011 December 1, 29(34):4479-4481.
56. Rutgers E., Piccart-Gebhart M.J., Bogaerts J., Delaloge S., Veer L.V., Rubio I.T., et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011 December, 47(18):2742-2749.
57. Sparano J.A. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006 October, 7(4):347-350.
58. Gonzalez-Angulo A.M., Barlow W.E., Gralow J., Meric-Bernstam F., Hayes D.F., Moinpur C., et al. SWEOG S1007: a phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone recepton (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. J Clin Oncol 2011, 29(Suppl. 15). [abstract].